Solennia Natalitia Serenissimi Principis Ac Domini Domini Christi. Gvntheri Principis Schwarzbvrgici ... Cras Hora Octava Matvtina Avdita Orationibvs Pvblice Celebranda

SOLENNIA NATALITIA SERENISSIMI PRINCIPIS AC DOMINI DOMINI CHRISTI. GVNTHERI PRINCIPIS SCHWARZBVRGICI ... CRAS HORA OCTAVA MATVTINA AVDITA ORATIONIBVS PVBLICE CELEBRANDA Solennia Natalitia Serenissimi Principis Ac Domini Domini Christi. Gvntheri Principis Schwarzbvrgici ... Cras Hora Octava Matvtina Avdita Orationibvs Pvblice Celebranda ([1]) Titelseite ([1]) Text ([3]

Zu einer dem höchst erfreulichsten Geburthsfeste des Durchlauchtigsten Fürsten und Herrn Herrn Christian Günthers Fürsten zu Schwarzburg ... Unsers gnädigsten Fürsten und Herrn unterthänigst gewidmeten Redeübung werden alle hohe und vornehme Patronen, Gönner und Freunde unsers Lyceums gehorsamst eingeladen

ZU EINER DEM HÖCHST ERFREULICHSTEN GEBURTHSFESTE DES DURCHLAUCHTIGSTEN FÜRSTEN UND HERRN HERRN CHRISTIAN GÜNTHERS FÜRSTEN ZU SCHWARZBURG ... UNSERS GNÄDIGSTEN FÜRSTEN UND HERRN UNTERTHÄNIGST GEWIDMETEN REDEÜBUNG WERDEN ALLE HOHE UND VORNEHME PATRONEN, GÖNNER UND FREUNDE UNSERS LYCEUMS GEHORSAMST EINGELADEN Zu einer dem höchst erfreulichsten Geburthsfeste des Durchlauchtigsten Fürsten und Herrn Herrn Christian Günthers Fürsten zu Schwarzburg ... Unsers gnädigsten Fürsten und Herrn unterthänigst gewidmeten Redeübung werden alle hohe und vornehme Patronen, Gönner und Freunde unsers Lyceums gehorsamst eingeladen ([1]) Titelseite ([1]) Text ([3]

Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study

Background!#!Although multiparametric magnetic resonance imaging (mpMRI) is recommended for primary risk stratification and follow-up in Active Surveillance (AS), it is not part of common AS inclusion criteria. The objective was to compare AS eligibility by systematic biopsy (SB) and combined MRI-targeted (MRI-TB) and SB within real-world data using current AS guidelines.!##!Methods!#!A retrospective multicenter study was conducted by a German prostate cancer (PCa) working group representing six tertiary referral centers and one outpatient practice. Men with PCa and at least one MRI-visible lesion according to Prostate Imaging Reporting and Data System (PI-RADS) v2 were included. Twenty different AS inclusion criteria of international guidelines were applied to calculate AS eligibility using either a SB or a combined MRI-TB and SB. Reasons for AS exclusion were assessed.!##!Results!#!Of 1941 patients with PCa, per guideline, 583-1112 patients with PCa in both MRI-TB and SB were available for analysis. Using SB, a median of 22.1% (range 6.4-72.4%) were eligible for AS. Using the combined approach, a median of 15% (range 1.7-68.3%) were eligible for AS. Addition of MRI-TB led to a 32.1% reduction of suitable patients. Besides Gleason Score upgrading, the maximum number of positive cores were the most frequent exclusion criterion. Variability in MRI and biopsy protocols potentially limit the results.!##!Conclusions!#!Only a moderate number of patients with PCa can be monitored by AS to defer active treatment using current guidelines for inclusion in a real-world setting. By an additional MRI-TB, this number is markedly reduced. These results underline the need for a contemporary adjustment of AS inclusion criteria

LifeTime and improving European healthcare through cell-based interceptive medicine

AUTEURS : LifeTime Community Working GroupsInternational audienceHere we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade